American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 724-728.e1 , November 2008

In Vitro Evaluation of Combination Antifungal Activity against Fusarium Species Isolated from Ocular Tissues of Keratomycosis Patients

  • Li Li
    • ,
  • Zhiqun Wang
    • ,
  • Ran Li
    • ,
  • Shiyun Luo
    • ,
  • Xuguang Sun

      Affiliations

    • Corresponding Author InformationInquiries to Xuguang Sun, Department of Ocular Microbiology, Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China

,Accepted 7 June 2008.

References 

  1. Ritterband DC, Seedor JA, Shah MK, Koplin RS, McCormick SA. Fungal keratitis at the New York Eye and Ear Infirmary. Cornea. 2006;25:264–267
  2. Gopinathan U, Garg P, Fernandes M, Sharma S, Athmanathan S, Rao GN. The epidemiological features and laboratory results of fungal keratitis: a 10-year review at a referral eye care center in South India. Cornea. 2002;21:555–559
  3. Xuguang S, Zhixin W, Zhiqun W, et al. Ocular fungal isolates and antifungal susceptibility in Northern China. Am J Ophthalmol. 2007;143:131–133
  4. Rosa RH, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in South Florida. Ophthalmology. 1994;101:1005–1013
  5. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol. 2007;125:789–793
  6. Therese KL, Bagyalakshmi R, Madhavan HN, Deepa P. In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole, and ketoconazole against ocular fungal isolates. Indian J Med Microbiol. 2006;24:273–279
  7. Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced fusarium keratitis progressing to endophthalmitis. Cornea. 2003;22:300–303
  8. Baddley JW, Pappas PG. Antifungal combination therapy: clinical potential. Drugs. 2005;65:1461–1480
  9. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium Forming Filamentous Fungi (Proposed Standard. NCCLS Document M38-P). Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards; 2002;
  10. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of filamentous Fungi (Approved Standard. NCCLS Document M38-A). Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards; 2002;
  11. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol. 2003;149:296–305
  12. Vitale RG, Afeltra J, Dannaoui E. Antifungal combinations (Methods in molecular medicine). In:  Ernst EJ,  Rogers PD editor. Antifungal Agents: Methods and Protocols. Totowa, New Jersey: Humana Press Inc; 2005;p. 143–152
  13. Iyer SA, Tuli SS, Wagoner RC. Fungal keratitis: emerging trends and treatment outcomes. Eye Contact Lens. 2006;32:267–271
  14. Ganegoda N, Rao SK. Antifungal therapy for keratomycoses. Expert Opin Pharmacother. 2004;5:865–874
  15. Pfaller MA, Messer SA, Hollis RJ, Jones RN SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002;46:1032–1037
  16. Lass-Flörl C, Kofler G, Kropshofer G, et al. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 1998;42:497–502
  17. Ortoneda M, Capilla J, Javier Pastor F, Pujol I, Guarro J. In vitro interactions of licensed and novel antifungal drugs against Fusarium spp. Diagn Microbiol Infect Dis. 2004;48:69–71
  18. Rothe A, Seibold M, Hoppe T, et al. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394–397
  19. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501–517
  20. Sugar AM. Use of amphotericin B with azole antifungal drugs: what are we doing?. Antimicrob Agents Chemother. 1995;39:1907–1912
  21. Ghannoum MA, Spellberg BJ, Ibrahim AS, et al. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole. Antimicrob Agents Chemother. 1994;38:2029–2033
  22. Te Welscher YM, Ten Napel HH, Balagué MM, et al. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008;283:6393–6401

PII: S0002-9394(08)00460-1

doi: 10.1016/j.ajo.2008.06.008

American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 724-728.e1 , November 2008

Article Tools